Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

Massard, Christophe; Chi, Kim Nguyen; Castellano, Daniel; de Bono, Johann; Gravis, Gwenaelle; Dirix, Luc; Machiels, Jean-Pascal; Mita, Alain; Mellado, Begoña; Turri, Sabine; Maier, Joan; Csonka, Denes; Chakravartty, Arunava; Fizazi, Karim

doi:10.1016/j.ejca.2017.05.003

Corrigendum to 'Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer' [European Journal of Cancer 76 (2017) 36-44].

Massard, Christophe

;

Chi, Kim Nguyen

;

Castellano, Daniel

;

de Bono, Johann

;

Fizazi, Karim

;et.al.

(2017) European Journal of Cancer — Vol. 81, p. 242 (2017)

Files

2017_Massard_Eur_J_Cancer.pdf

Restricted Access
Adobe PDF
175.21 KB

Request a copy

Details

Authors

Massard, Christophe
Author
Chi, Kim Nguyen
Author
Castellano, Daniel
Author
de Bono, Johann
Author
Machiels, Jean-PascalUCLouvain
Author
Fizazi, Karim
Author

Affiliations

Citations

APA
Chicago
FWB

Massard, C., Chi, K. N., Castellano, D., de Bono, J., Gravis, G., Dirix, L., Machiels, J.-P., Mita, A., Mellado, B., Turri, S., Maier, J., Csonka, D., Chakravartty, A., & Fizazi, K. (2017). Corrigendum to ‘Phase Ib dose-finding study of abiraterone acetate plus buparlisib (BKM120) or dactolisib (BEZ235) in patients with castration-resistant prostate cancer’ [European Journal of Cancer 76 (2017) 36-44]. European Journal of Cancer, 81, 242. https://doi.org/10.1016/j.ejca.2017.05.003 (Original work published 2017)